Questions or comments on this presentation can be addressed to You can pick and choose the elements.

Slides:



Advertisements
Similar presentations
Community Pharmacy – Call to Action Derbyshire / Nottinghamshire Area Team.
Advertisements

Chronic Medication Service (CMS). Programme Introduction Pharmaceutical Care Planning - Ray ePharmacy Programme – Dawn, IM & T Workshops – Niall, Michelle,
The vision for NHS Community Pharmacies The path to improved patient care.
Chronic Obstructive Pulmonary Disease Research Opportunity Chronic Obstructive Pulmonary Disease (COPD) Dr Ian Williams Greater Metro South Brisbane Medicare.
Improving Inhaler Technique through Community Pharmacy Service Greater Manchester Area Team January 2015.
Mike Keen, CEO, Kent LPC. Why is change needed? NHS England states that: Primary care services face increasingly unsustainable pressures Community pharmacy.
The Scale, Causes and Costs of Medicines Waste – a national perspective Northamptonshire Medicine Waste Management Conference, 28 th November 2012 David.
Disease State Management The Pharmacist’s Role
Improving health outcomes across England by providing improvement and change expertise How to Measure Patient Activation Measuring Patient Activation In.
Nottingham North and East Strategy Medicines Management 2014/15.
The challenge of medicines non-adherence. 2 How is adherence defined? WHO definition: ‘the extent to which a person’s behaviour – taking medication, following.
Improving Inhaler Technique through Community Pharmacy Service Greater Manchester Area Team Autumn 2014.
Questions or comments on this presentation can be addressed to You can pick and choose the elements.
Managing Medicines Use by PBC Groups in West Hertfordshire Dr Alison Davies.
Clare A Mackie Centre for Partnerships in Medicines for Health Economic Evaluation of a RCT of a ‘Medication Review Clinic’ in Patients Receiving Repeat.
Clinical Pharmacy II Lobna Al Juffali,MSc Fall-2009.
1 “Medicines use review conducted in community pharmacy" Professor Ian Chi Kei Wong Department of Health Public Health Career Scientist The School of Pharmacy.
Think Pharmacy Sue Sharpe CEO PSNC. Outline of Talk The Vision for the future community pharmacy The four domains for pharmacy services  Medicines Optimisation.
THE ROLE OF THE HEART FAILURE SPECIALIST NURSE NHS Grampian Heart Failure Nurses November 2008.
Complex Care Management In Practice Dunblane Tuesday 6 th November 2007.
Implementing NICE guidance
HRET/K-HEN Readmissions Race Office Hour Building a Multidisciplinary Care Transitions Team January 25, 2013.
MEDICINES and Older People Hira Singh Prescribing Adviser (Middlesbrough PCT and Redcar & Cleveland PCT Medicines Management Team) March 2008.
The Pharmaceutical Care of Patients with Long Term Conditions Deirdre Watt Team Leader, Community Pharmacy Scottish Government.
Questions or comments on this presentation can be addressed to You can pick and choose the elements.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Pharmacists’ Expanded Scope of Practice in Canada as of Oct 2014 Source: Canadian Pharmacists Association.
The Value of Medication Therapy Management Services.
Medication Adherence The following module is designed as a basic overview of medication adherence for providers of healthcare, particularly those in a.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
T HE ROLE OF COMMUNITY PHARMACISTS IN WASTE REDUCTION AND MEDICINES OPTIMIZATION Mukesh Lad, Chair 28 November 2012.
Repeat Dispensing Sue Carter Regional Tutor Hampshire and IOW 1.
Questions or comments on this presentation can be addressed to You can pick and choose the elements.
The NHS Constitution: A consultation on new patient rights.
Medicines optimisation – a research pharmacist’s perspective Dr David Alldred Senior Lecturer in Pharmacy Practice 23 January 2015Bradford School of Pharmacy1.
High Impact Changes. Prioritize alcohol within LAAs and NHS Operating Framework – Vital Signs Improve treatment Review pathways and access – NATMS Evidence.
New Zealand Pharmacy Services Andi Shirtcliffe B. Pharm, PG Dip (Clin) Pharm, Reg Pharm NZ Chief Advisor – Pharmacy, New Zealand Ministry of Health.
Knowledge, Attitude and Behaviour of prescribers after the introduction of the treatment guidelines in South Africa Pillay T, Hill SR University of Newcastle.
SNAP Scottish National Audit Project CE Bucknall Chair, Bicollegiate Physicians Quality of Care Committee, on behalf of project team.
Medication Therapy Management Programs in Community Pharmacy Community Pharmacy October 17, 2006 Kurt A. Proctor, Ph.D., RPh Chief Operating Officer Community.
Improving the effectiveness of integrated care teams Rob Darracott Pharmacy Voice.
Community Pharmacy Cheshire & Wirral (CPCW) Helen Murphy Chief Executive Officer Community Pharmacy Cheshire and Wirral.
Educational Solutions for Workforce Development Pharmacy Significant Event Analysis Fiona McMillan Lead Pharmacist Educational Development April 2014.
South Central Respiratory Project MK Report 10 th October 2011 Nikki Hughes Community Pharmacy Lead NHS Milton keynes.
1 CHRONIC CONDITION SELF-MANAGEMENT FLINDERS HUMAN BEHAVIOUR & HEALTH RESEARCH UNIT THE FLINDERS MODEL.
Putting Patients at the Centre of Care What can my Community Pharmacist do for me? Dr Tarlochan Gill Chairman, Kent & Medway Pharmacy Local Professional.
Herefordshire CCG Putting the patient at the heart of everything we do1 More information can be found at
Educational solutions for the NHS pharmacy workforce Medicines Optimisation: Helping patients to make the most of medicines Sue Carter Regional Tutor
Training for organisations participating in Peer Review of Paediatric Diabetes.
Think Pharmacy Sue Sharpe CEO PSNC. Outline of Talk The Vision for the future community pharmacy The four domains for pharmacy services  Medicines Optimisation.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
Community Pharmacy: local healthcare Kath Gulson Chief Officer Halton, St Helens and Knowsley Local Pharmaceutical Committee
Medicines adherence Implementing NICE guidance 2009 NICE clinical guideline 76.
Read and then delete this slide This PSNC slide deck contains information on community pharmacy and the services it provides It is designed to be used.
Safety in Medicines: Raising the profile with the Royal Pharmaceutical Society Liz Rawlins Communications Officer 9 May 2011.
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
European Community Pharmacy Blueprint A perspective from general practice Professor Tony Avery.
Documentation in Practice Dept. of Clinical Pharmacy.
Pharmacy White Paper Building on Strengths Delivering the Future Overview.
Long term oxygen therapy for patients with COPD – community resources T McCarthy, M O’Connor, on behalf of the National COPD Strategy Group Population.
The challenge of medicines
Strategies to Modernize State Medicaid Programs, Utah’s Medicaid Transformation By Lisa V. Hulbert R.Ph. Transformation Program Manager Utah Medicaid.
Think Pharmacy Sue Sharpe CEO PSNC.
Prescribing.
Nottinghamshire & Derbyshire GP / Pharmacy Transformation Programme Unlocking the Potential of Community Pharmacy Cathy Quinn Pharmacist Lead Newark &
Clinical Pharmacy II.
NHS Community Pharmacy Contractual Framework
MUR and NMS Respiratory Toolkit.
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Victoria Gemmell1 Professor Alex Mullen2
Presentation transcript:

Questions or comments on this presentation can be addressed to You can pick and choose the elements of the presentation that suit the needs of your event / discussion with GP practice colleagues A document summarising the contract changes for GP practice teams can be downloaded from the PSNC website Read and delete this slide…

A guide to MURs for GPs can be downloaded from _murs _murs Documents summarising the work of community pharmacy for GP practice teams (and a document describing GP practices for pharmacy teams) can be downloaded from the PSNC website al_guides Last updated: 26 th November 2011 Read and delete this slide…

The NHS New Medicine Service and targeted MURs NHS Community Pharmacy Contractual Framework

The introduction of a New Medicine Service (NMS) The introduction of nationally targeted Medicines Use Reviews (MURs) Service changes were introduced on 1 st Oct 2011 Changes to the pharmacy contract

Estimates vary on the frequency of non-adherence: – Between 33% and 50% of medicines for LTCs are not used as recommended – 20-30% don’t adhere to regimens that are curative or relieve symptoms – 30-40% fail to follow regimens designed to prevent health problems It has been suggested that increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments Haynes R, McDonald H, Garg A, Montague P. (2002). Interventions for helping patients to follow prescriptions for medications. The Cochrane Database of Systematic Reviews, 2, CD The challenge of non-adherence

Research published in 2004 showed that 10 days after starting a new medicine: – 7% of patients had completely stopped taking the medicine (completely non- adherent) – 30% of patients still taking the medicine were non-adherent – 45% of non-adherence was intentional (the remainder was unintentional) – 61% of patients expressed a substantial and sustained need for further information – 66% of patients still taking their medicine reported at least one problem with it: Side effects (50%) Concerns about the medication (43%) Difficulties with the practical aspects of taking the medication (7%) Patients’ problems with new medication for chronic conditions. Barber N et al. Qual Saf Health Care 2004;13: Non-adherence to newly prescribed medicines

Research was published in 2006 reporting on a randomised controlled trial (n=500) on which the NMS is based At 4-week follow-up, non-adherence was significantly lower in the intervention group compared to control (9% versus 16%, P = 0.032) The number of patients reporting medicine-related problems was significantly lower in the intervention group compared to the control (23% vs. 34%, P = 0.021) Intervention group patients also had more positive beliefs about their new medicine, as shown by their higher score on the ‘‘necessity-concerns differential’’ (5.0 vs. 3.5, P = 0.007) Patient-centred advice is effective in improving adherence to medicines. Clifford S et al. Pharm World Sci 2006;28: The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. Elliott R A et al. Pharm World Sci 2008;30:17-23 The ‘NMS’ research

Provides early support to patients to maximise the benefits of prescribed medication Proof of concept research shows that an intervention by a pharmacist can help to improve patients’ adherence In the research patients who used the service experienced fewer medicines problems and made less use of other NHS services, saving money and GP time The cost of the service is offset by savings created by community pharmacy medicines procurement New Medicine Service

PSNC and NHS Employers envisage that the successful implementation of NMS will: – improve patient adherence – increase patient engagement with their condition and medicines – reduce medicines wastage – reduce hospital admissions due to adverse events from medicines – lead to increased Yellow Card reporting – receive positive assessment from patients – support the development of outcome and/or quality measures for community pharmacy Potential benefits

Three stage process 1.Patient engagement (day 0) 2.Intervention (approx. day 14) 3.Follow up (approx. day 28) Opportunity to provide healthy living advice at each stage NMS – outline service spec

Follows the prescribing of a new medicine for: ₋Asthma or COPD ₋Diabetes (Type 2) ₋Antiplatelet / Anticoagulant therapy ₋Hypertension Recruitment by pharmacy or via referral NMS – Patient engagement

Intervention typically day 7 – 14 – Face to face in a consultation area or over the phone – Semi-structured interview technique to: assess adherence identify problems identify the patient’s need for further information and support – Pharmacist provides advice and support agrees follow up agrees solution(s) refers to GP (only where absolutely necessary) NMS – Intervention

Follow up typically between 14 and 21 days after the Intervention – Face to face in a consultation area or over the phone – Semi-structured interview technique to: assess adherence identify problems identify the patient’s need for further information and support – Pharmacist provides advice and support Patient adherent Patient non-adherent provide more advice and support or refer to GP (using nationally agreed NMS Feedback form) NMS – Follow up

Pharmacies must have a consultation area that meets the requirements for the MUR service in order to provide the NMS Premises requirements

Pharmacy contractors or their representative must communicate with local GP Practices before providing NMS LPCs may support contractors with this task and may work with the Local Medical Committee A briefing document for GP Practice teams is available from the PSNC website Communicating with GP practices

National NMS Feedback Form designed by GPC/PSNC/NHS Employers Referrals will only be made when absolutely necessary GPC advised that pharmacists should refer to the practice, rather than suggesting patients make an appointment with their GP This approach allows the practice to determine how they want to deal with the issue raised in the Feedback Form Referring to the GP practice

GPs will also only be sent forms if an issue is identified that the GP needs to address, Dr Bill Beeby, chairman of the GPC clinical and prescribing committee, told GPonline.com. He said the final version of the form would be easy for GPs to gain information from and would improve patient safety. ‘The form will be on one side of paper,’ he said. ‘GPs won’t be inundated with non-reports.’ Reports would only be sent when the pharmacist identified an issue with a patient initiated on a medicine that the GP needed to deal with, he said. ‘For the vast majority you won’t get a piece of paper.’ wont-inundated-new-pharmacy-report-forms/ Referring to the GP practice

Laurence Buckman, Chairman of the GPC “If both professions can form stronger links it will benefit both them and their patients. LMCs and LPCs are ideally placed to make this happen.” The BMA viewpoint

Dr Clare Gerada, Chair of the Royal College of General Practitioners “Patients do sometimes experience problems with their medicines and, through the New Medicine Service, GPs and pharmacists will work in partnership to ensure those that need support receive it. This will result in improving the care we provide to our patients, and in turn our patients’ health.” The RCGP viewpoint

MURs aim to improve a patient’s knowledge, understanding and use of their medicines From 1 October 2011 pharmacies must ensure that at least 50% of the MURs they provide are targeted on patients who: – are taking “high risk medicines” (diuretics, NSAIDs, antiplatelets and anticoagulants) – have been recently discharged from hospital with an amended medicines regimen. Ideally patients who are discharged from hospital will receive an MUR within four weeks of discharge but in certain circumstances the MUR can take place within eight weeks of discharge – have respiratory disease Targeted MURs

As now, MURs will cover all the patient’s medicines not just those that fall within a target group Pharmacists will still be able to provide MURs to patients who fall outside of the target groups who they think would benefit from the intervention Targeted MURs

Briefing documents for GP Practice teams written by GPC / PSNC / NHS Employers are available from the PSNC website Briefing documents

Questions, comments and next steps Working together…